Logo image of CNTB

CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CNTB - KYG235491019 - Common Stock

2.15 USD
-0.08 (-3.59%)
Last: 1/9/2026, 8:00:00 PM
2.15 USD
0 (0%)
After Hours: 1/9/2026, 8:00:00 PM
Fundamental Rating

2

CNTB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. While CNTB seems to be doing ok healthwise, there are quite some concerns on its profitability. CNTB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTB had negative earnings in the past year.
CNTB had negative earnings in each of the past 5 years.
CNTB had a negative operating cash flow in each of the past 5 years.
CNTB Yearly Net Income VS EBIT VS OCF VS FCFCNTB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M -1B

1.2 Ratios

The Return On Assets of CNTB (-23.20%) is better than 73.48% of its industry peers.
CNTB has a Return On Equity of -28.22%. This is in the better half of the industry: CNTB outperforms 77.84% of its industry peers.
Industry RankSector Rank
ROA -23.2%
ROE -28.22%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTB Yearly ROA, ROE, ROICCNTB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

CNTB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTB Yearly Profit, Operating, Gross MarginsCNTB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

More info and screens

6

2. Health

2.1 Basic Checks

CNTB does not have a ROIC to compare to the WACC, probably because it is not profitable.
CNTB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNTB Yearly Shares OutstandingCNTB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CNTB Yearly Total Debt VS Total AssetsCNTB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

CNTB has an Altman-Z score of -1.73. This is a bad value and indicates that CNTB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.73, CNTB perfoms like the industry average, outperforming 53.03% of the companies in the same industry.
There is no outstanding debt for CNTB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.73
ROIC/WACCN/A
WACC8.81%
CNTB Yearly LT Debt VS Equity VS FCFCNTB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 5.48 indicates that CNTB has no problem at all paying its short term obligations.
The Current ratio of CNTB (5.48) is comparable to the rest of the industry.
A Quick Ratio of 5.48 indicates that CNTB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.48, CNTB is in the better half of the industry, outperforming 60.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 5.48
CNTB Yearly Current Assets VS Current LiabilitesCNTB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

1

3. Growth

3.1 Past

CNTB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.90%, which is quite impressive.
EPS 1Y (TTM)74.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.88% on average over the next years. This is quite good.
Based on estimates for the next years, CNTB will show a very negative growth in Revenue. The Revenue will decrease by -18.22% on average per year.
EPS Next Y-212.62%
EPS Next 2Y-57.8%
EPS Next 3Y-30.47%
EPS Next 5Y10.88%
Revenue Next Year-99.83%
Revenue Next 2Y-35.07%
Revenue Next 3Y-10.13%
Revenue Next 5Y-18.22%

3.3 Evolution

CNTB Yearly Revenue VS EstimatesCNTB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CNTB Yearly EPS VS EstimatesCNTB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTB. In the last year negative earnings were reported.
Also next year CNTB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTB Price Earnings VS Forward Price EarningsCNTB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTB Per share dataCNTB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as CNTB's earnings are expected to decrease with -30.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-57.8%
EPS Next 3Y-30.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CONNECT BIOPHARMA HOLDINGS L

NASDAQ:CNTB (1/9/2026, 8:00:00 PM)

After market: 2.15 0 (0%)

2.15

-0.08 (-3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners39.14%
Inst Owner Change0%
Ins Owners0.7%
Ins Owner ChangeN/A
Market Cap119.80M
Revenue(TTM)26.03M
Net Income(TTM)-15.63M
Analysts85.45
Price Target8.06 (274.88%)
Short Float %0.61%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.2%
Min EPS beat(2)69.43%
Max EPS beat(2)74.98%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.94%
EPS NY rev (1m)-15.61%
EPS NY rev (3m)-2.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)54.55%
Revenue NY rev (3m)1733.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.6
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 2.17
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-3.92
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.47
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.2%
ROE -28.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 5.48
Altman-Z -1.73
F-ScoreN/A
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)182.41%
Cap/Depr(5y)444.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-212.62%
EPS Next 2Y-57.8%
EPS Next 3Y-30.47%
EPS Next 5Y10.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-99.83%
Revenue Next 2Y-35.07%
Revenue Next 3Y-10.13%
Revenue Next 5Y-18.22%
EBIT growth 1Y71.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.54%
OCF growth 3YN/A
OCF growth 5YN/A

CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ

Can you provide the ChartMill fundamental rating for CONNECT BIOPHARMA HOLDINGS L?

ChartMill assigns a fundamental rating of 2 / 10 to CNTB.


What is the valuation status for CNTB stock?

ChartMill assigns a valuation rating of 0 / 10 to CONNECT BIOPHARMA HOLDINGS L (CNTB). This can be considered as Overvalued.


What is the profitability of CNTB stock?

CONNECT BIOPHARMA HOLDINGS L (CNTB) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CONNECT BIOPHARMA HOLDINGS L?

The Earnings per Share (EPS) of CONNECT BIOPHARMA HOLDINGS L (CNTB) is expected to decline by -212.62% in the next year.